d -Dimer Testing to Determine the Duration of Anticoagulation Therapy
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The optimal duration of oral anticoagulation in patients with idiopathic venous thromboembolism is uncertain. Testing of D-dimer levels may play a role in the assessment of the need for prolonged anticoagulation. METHODS: We performed D-dimer testing 1 month after the discontinuation of anticoagulation in patients with a first unprovoked proximal deep-vein thrombosis or pulmonary embolism who had received a vitamin K antagonist for at least 3 months. Patients with a normal D-dimer level did not resume anticoagulation, whereas those with an abnormal D-dimer level were randomly assigned either to resume or to discontinue treatment. The study outcome was the composite of recurrent venous thromboembolism and major bleeding during an average follow-up of 1.4 years. RESULTS: The D-dimer assay was abnormal in 223 of 608 patients (36.7%). A total of 18 events occurred among the 120 patients who stopped anticoagulation (15.0%), as compared with 3 events among the 103 patients who resumed anticoagulation (2.9%), for an adjusted hazard ratio of 4.26 (95% confidence interval [CI], 1.23 to 14.6; P=0.02). Thromboembolism recurred in 24 of 385 patients with a normal D-dimer level (6.2%). Among patients who stopped anticoagulation, the adjusted hazard ratio for recurrent thromboembolism among those with an abnormal D-dimer level, as compared with those with a normal D-dimer level, was 2.27 (95% CI, 1.15 to 4.46; P=0.02). CONCLUSIONS: Patients with an abnormal D-dimer level 1 month after the discontinuation of anticoagulation have a significant incidence of recurrent venous thromboembolism, which is reduced by the resumption of anticoagulation. The optimal course of anticoagulation in patients with a normal D-dimer level has not been clearly established. (ClinicalTrials.gov number, NCT00264277 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Mutation in blood coagulation factor V associated with resistance to activated protein C
Bertina, R. M., Koeleman, B. P. C., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., & Reitsma, P. H. (1994) · Nature · doi:10.1038/369064a0 · Cited by 3,783
Poort, Sr., Rosendaal, F., Reitsma, P., & Bertina, R. (1996) · Blood · doi:10.1182/blood.v88.10.3698.bloodjournal88103698 · Cited by 3,079
Heit, J. A., Mohr, D. N., Silverstein, M. D., Petterson, T. M., O'Fallon, W. M., & Melton, L. J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.6.761 · Cited by 1,352
Palareti, G., Leali, N., Coccheri, S., Poggi, M., Manotti, C., D'Angelo, A., Pengo, V., Erba, N., Moia, M., Ciavarella, N., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)01109-9 · Cited by 1,333
Self-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072
Schulman, S., Rhedin, A.-S., Lindmarker, P., Carlsson, A., Lärfars, G., Nicol, P., Loogna, E., Svensson, E., Ljungberg, B., Walter, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322501 · Cited by 932
Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis
Agnelli, G., Prandoni, P., Santamaria, M. G., Bagatella, P., Iorio, A., Bazzan, M., Moia, M., Guazzaloca, G., Bertoldi, A., Tomasi, C., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450302 · Cited by 591
Self-citationO'Neill, D. D., Westerman, D. P., & Sacco, W. (1966) · doi:10.21236/ad0635168 · Cited by 566
Pinede, L., Ninet, J., Duhaut, P., Chabaud, S., Demolombe-Rague, S., Durieu, I., Nony, P., Sanson, C., & Boissel, J.-P. (2001) · Circulation · doi:10.1161/01.cir.103.20.2453 · Cited by 408
Research works printed but not linked: 1
- Kearon C, 2003, CMAJ, 168, 183
Cited by
Items 101–200 of 619
Bang, O. Y., Chung, J., Lee, M. J., Kim, S. J., Cho, Y. H., Kim, G., Chung, C., Lee, K. H., Ahn, M., & Moon, G. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159170 · Cited by 70
“[44] [45] D-dimer levels are nonspecific and may change with treatment or complications such as infection.”
BackgroundTreatment of DVT: how long is enough and how do you predict recurrence
Agnelli, G., & Becattini, C. (2007) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-007-0103-z · Cited by 70
D-dimer before chemotherapy might predict venous thromboembolism
Arpaia, G., Carpenedo, M., Verga, M., Mastrogiacomo, O., Fagnani, D., Lanfredini, M., Milani, M., & Cimminiello, C. (2009) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e32831bc2de · Cited by 69
Gal, G. L., Kovacs, M., Carrier, M., Do, K., Kahn, S., Wells, P., Anderson, D., Chagnon, I., Solymoss, S., Crowther, M., et al. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-10-0685 · Cited by 68
Stein, P. D., & Matta, F. (2010) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2010.03.002 · Cited by 69
Siragusa, S. M., Malato, A., Saccullo, G., Iorio, A., Ianni, M. D., Caracciolo, C., Coco, L. L., Raso, S., Santoro, M., Guarneri, F. P., et al. (2011) · American Journal of Hematology · doi:10.1002/ajh.22156 · Cited by 67
Self-citationFranco‐Moreno, A., Navarro, M. J. G., Sánchez, J. O., Díaz, R. M. M., Cerezo, E. M., Aracil, C. L. D. A., Clotet, N. C., Fraile, I. P., García, S., Hernández, C. M., et al. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.12.010 · Cited by 69
Tromeur, C., Sanchez, O., Presles, É., Pernod, G., Bertoletti, L., Jégo, P., Duhamel, E., Provost, K., Parent, F., Robin, P., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.01202-2017 · Cited by 70
Resolution of left atrial appendage thrombus with apixaban
Kawakami, T., Kobayakawa, H., Ohno, H., Tanaka, N., & Ishihara, H. (2013) · Thrombosis Journal · doi:10.1186/1477-9560-11-26 · Cited by 63
“Recently, SF and D-dimer levels have been considered useful for diagnosis of thrombosis [8-14].”
BackgroundZhang, P.-P., Sun, J., Wang, X., Liu, X.-M., & Li, K. (2013) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2013.06.008 · Cited by 63
Gremmel, T., Ay, C., Seidinger, D., Pabinger, I., Panzer, S., & Koppensteiner, R. (2011) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2011.05.097 · Cited by 62
Assessing the risk of recurrent venous thromboembolism – a practical approach
Keo, H. H., Fahrni, J., Husmann, M. J. W., & Gretener, S. B. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s83718 · Cited by 81
Long-term outcomes after pulmonary embolism: current knowledge and future research
Kahn, S. R., Houweling, A. H., Granton, J. T., Rudski, L., Dennie, C. J., & Hirsch, A. (2014) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000070 · Cited by 63
Latella, J., Desmarais, S., Miron, M. ‐., Roussin, A., Joyal, F., Kassis, J., Solymoss, S., Desjardins, L., Ginsberg, J., & Kahn, S. R. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04001.x · Cited by 60
Use of D‐dimer in oral anticoagulation therapy
Zhang, L., Long, Y., Xiao, H., Yang, J., Toulon, P. A., & Zhang, Z. (2018) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12864 · Cited by 63
Unprovoked recurrent venous thrombosis: prediction by D‐dimer and clinical risk factors
Baglin, T. P., Palmer, C. R., Luddington, R. J., & Baglin, C. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.02889.x · Cited by 59
Cosmi, B., Legnani, C., Iorio, A., Pengo, V., Ghirarduzzi, A., Testa, S., Poli, D., Tripodi, A., & Palareti, G. (2010) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2009.11.022 · Cited by 57
Self-citationPoli, D., Antonucci, E., Ciuti, G., Abbate, R., & Prisco, D. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.02900.x · Cited by 57
Timp, J. F., Brækkan, S. K., Lijfering, W. M., Vlieg, A. V. H., Hansen, J., Rosendaal, F. R., le Cessie, S., & Cannegieter, S. C. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002883 · Cited by 60
Jara‐Palomares, L., Solier-López, A., Elías-Hernández, T., Asensio-Cruz, M. I., Blasco-Esquivias, I., Sánchez‐López, V., de la Borbolla, M. R., Arellano‐Orden, E., Suárez-Valdivia, L., Marín-Romero, S., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0269-5 · Cited by 59
Áinle, F. N., & Kevane, B. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002268 · Cited by 67
“Douketis et al 2011 (49) Patient-level meta-analysis N/R 1.”
BackgroundWhole blood gene expression analyses in patients with single versus recurrent venous thromboembolism
LEWIS, D. A., Stashenko, G. J., Akay, O. M., Price, L. I., Owzar, K., Ginsburg, G. S., Chi, J., & Ortel, T. L. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.06.003 · Cited by 55
“associated with a low rate of recurrence [9].”
BackgroundGonzález-Fajardo, J. A., Martín-Pedrosa, M., Castrodeza, J., Tamames, S., & Puerta, C. V. (2008) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2008.05.033 · Cited by 55
Biomarkers of deep venous thrombosis
Hou, H., Ge, Z., Ying, P., Dai, J. M., Shi, D., Xu, Z., Chen, D., & Jiang, Q. Y. (2012) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-012-0721-y · Cited by 56
“Persistent high levels of D-dimer, FVIII, and TG prognosticate that individuals are at risk of not only first DVT, but also recurrent DVT [37, 38, 44, 46, 59, 60].”
BackgroundMarik, P. E., & Cavallazzi, R. (2015) · PLOS ONE · doi:10.1371/journal.pone.0143252 · Cited by 53
Comparison of Enoxaparin and Warfarin for Secondary Prevention of Cancer-Associated Stroke
Jang, H., Lee, J. J., Lee, M. J., Ryoo, S., Yoon, C. H., Kim, G., Chung, C., Lee, K. H., Bang, O. Y., & Kim, S. J. (2015) · Journal of Oncology · doi:10.1155/2015/502089 · Cited by 53
“In addition, D-dimer levels are useful for prognostication as well as judging of the effect of anticoagulation treatment in patients with deep vein thrombosis, pulmonary embolism, and cancer-associated stroke [5, 25–27].”
BackgroundThe Diagnosis and Management of Early Deep Vein Thrombosis
Hansrani, V., Khanbhai, M., & McCollum, C. N. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_103 · Cited by 54
From Classical Laboratory Parameters to Novel Biomarkers for the Diagnosis of Venous Thrombosis
Anghel, L., Sascău, R. A., Radu, R., & Stătescu, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061920 · Cited by 55
“4 years after at least 3 months of therapy with warfarin [38].”
BackgroundKhan, F. A., Tritschler, T., Kimpton, M., Wells, P. S., Kearon, C., Weitz, J. I., Buller, H. R., Raskob, G. E., Ageno, W., Couturaud, F., et al. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15491 · Cited by 58
Self-citationThe use of D-dimer in specific clinical conditions: A narrative review
Bruinstroop, E., van de Ree, M. A., & Huisman, M. V. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2008.12.004 · Cited by 58
“Can you safely exclude PE in this patient with a normal D-dimer? D-dimer has been reported to be elevated in a large amount of the patients one month after completion of a six month anticoagulation drug course [18].”
BackgroundD-dimer level for predicting the in-hospital mortality in liver cirrhosis: A retrospective study
Li, Y., Qi, X., Li, H., Dai, J., Deng, H., Li, J., Peng, Y., Liu, X., Sun, X., & Guo, X. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3930 · Cited by 56
“In addition, D-dimer levels are used for predicting the risk of recurrent venous thromboembolism and determining the duration of anticoagulation therapy in these patients (4-6).”
Legnani, C., Cini, M., Guazzaloca, G., Palareti, G., & Cosmi, B. (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-08-0559 · Cited by 55
“While in the PROLONG (15, 16) and AESOPUS (21) studies the method of Prandoni et al. (23) was adopted, in the DACUS (20) study RVO was defined as a residual thrombus occupying more than 40% of the vein area calculated in the absence of compression.”
BackgroundMethodSelf-citationD-dimer testing: A narrative review
Wauthier, L., Favresse, J., Hardy, M. J., Douxfils, J., Gal, G. L., Roy, P., van Es, N., Ay, C., Cate, H. T., Lecompte, T., et al. (2023) · Advances in clinical chemistry · doi:10.1016/bs.acc.2023.02.006 · Cited by 58
OSA Is a Risk Factor for Recurrent VTE
Alonso‐Fernández, A., Suquia, A. G., de la Peña, M., Casitas, R., Piérola, J., Barceló, A., Soriano, J. B., Fernández‐Capitán, C., Martínez-Cerón, E., Carrera, M., et al. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.07.011 · Cited by 51
“1292 Original Research episode, cancer, continued estrogen use, vena cava filters, high post-anticoagulation plasma D-dimer levels, male sex, and obesity.(10-21) The last two factors are well known clinical features associated with OSA.”
Lippi, G., Cervellin, G., Casagranda, I., Morelli, B., Testa, S., & Tripodi, A. (2013) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2013-0706 · Cited by 51
Self-citationFraser, K., Roy, N. C., Goumidi, L., Verdu, A., Suchon, P., Valentim, F. L., Trégouët, D., Morange, P., & Martin, J. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314480 · Cited by 50
Cosmi, B., Legnani, C., Cini, M., Favaretto, E., & Palareti, G. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2007.12.024 · Cited by 47
“Our previous observation that altered D-d after VKAwithdrawal is associated with a low risk of recurrent VTE [12] has been confirmed by other authors [13] and also by the randomized clinical study PROLONG [14].”
BackgroundResultInfluentialSelf-citationWang, Y., Xu, X., Zhao, X., & Yin, Z. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.10.015 · Cited by 47
(2008) · PubMed Central · Cited by 46
Biomarkers of Hypercoagulability and Inflammation in Childhood-Onset Arterial Ischemic Stroke
Bernard, T. J., Fenton, L. Z., Apkon, S. D., Boada, R., Wilkening, G. N., Wilkinson, C. C., Soep, J. B., Miyamoto, S. D., Tripputi, M., Armstrong, J., et al. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.10.034 · Cited by 45
Recurrent Venous Thromboembolism: What Is the Risk and How to Prevent It
Palareti, G. (2012) · Scientifica · doi:10.6064/2012/391734 · Cited by 47
“A prospective, collaborative, and randomized study (PROLONG study) was then performed to assess the predictive role of D dimer for recurrence aer a �rst episode of unprovoked VTE [157].”
BackgroundSelf-citationRisk of recurrence after a first venous thromboembolic event in young women
Laczkovics, C., Grafenhofer, H., Kaider, A., Quehenberger, P., Simanek, R., Mannhalter, C., Lechner, K., & Pabinger, I. (2007) · Haematologica · doi:10.3324/haematol.10967 · Cited by 46
Aspects of anticoagulation in children
Payne, J. H. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08225.x · Cited by 45
“Furthermore, a randomised trial showed that if D-dimers are persistently elevated at the end of a conventional period of anticoagulation then extension of anticoagulation is effective in reducing the risk of recurrence in adult patients (Palareti et al, 2006).”
BackgroundClinical scores to predict recurrence risk of venous thromboembolism
Eichinger, S., & Kyrle, P. A. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-05-0353 · Cited by 43
Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism
Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galiè, N., Pruszczyk, P., Bengel, F. M., Brady, A. J. B., Ferreira, D., Janssens, U., et al. (2008) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(09)60060-8 · Cited by 44
Venous Thromboembolism: Review of Clinical Challenges, Biology, Assessment, Treatment, and Modeling
Watson, C. T., Saaid, H., Vedula, V., Cardenas, J. C., Henke, P. K., Nicoud, F., Xu, X. Y., Hunt, B. J., & Manning, K. B. (2023) · Annals of Biomedical Engineering · doi:10.1007/s10439-023-03390-z · Cited by 46
“Plasmin digestion of fibrin yields D-dimer [45], a waste product that can be utilized as a marker for risk of recurrent VTE following treatment [46, 47].”
Rodger, M. A., Carrier, M., Gándara, E., & Gal, G. L. (2010) · Blood Reviews · doi:10.1016/j.blre.2010.06.001 · Cited by 44
Han, D., Hartaigh, B. Ó., Lee, J. H., Cho, I., Shim, C. Y., Chang, H., Hong, G., Ha, J., & Chung, N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153514 · Cited by 41
How I treat recurrent deep-vein thrombosis
Kyrle, P. A. (2015) · Blood · doi:10.1182/blood-2015-09-671297 · Cited by 42
Ensor, J., Riley, R. D., Jowett, S., Monahan, M., Snell, K. I., Bayliss, S., Moore, D., Fitzmaurice, D., & on behalf of the PIT-STOP collaborative group (2016) · Health Technology Assessment · doi:10.3310/hta20120 · Cited by 40
Cosmi, B., Legnani, C., Tosetto, A., Pengo, V., Ghirarduzzi, A., Testa, S., Prisco, D., Poli, D., Tripodi, A., & Palareti, G. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03955.x · Cited by 43
Self-citationAppropriate Use of D-dimer in Hospital Patients
Thachil, J. V., Fitzmaurice, D. A., & Toh, C. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.09.011 · Cited by 39
And the RIETE Investigators, Piovella, C., Valle, F. D., Trujillo‐Santos, J., Pesavento, R., López, L., Font, L., Valle, R., Nauffal, D., Monréal, M., et al. (2014) · Internal and Emergency Medicine · doi:10.1007/s11739-014-1073-8 · Cited by 43
Rabinovich, A., Cohen, J. M., & Kahn, S. R. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-11-0931 · Cited by 38
“Therefore, in controlled cohort studies, we used only the cohort of VTE patients and excluded the healthy controls.”
BackgroundInfluentialLegnani, C., Palareti, G., Cosmi, B., Cini, M., Tosetto, A., & Tripodi, A. (2008) · Haematologica · doi:10.3324/haematol.12320 · Cited by 48
Self-citationDiagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective
Pengo, V., & Denas, G. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.07.011 · Cited by 36
Self-citationZhang, K., Wang, P., Huang, W., Tang, S.-H., Xue, H., Wu, H., Zhang, Y., Yu, R., Dong, S., Chen, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52262-0 · Cited by 39
“To verify the generalization ability of the predictive model, we performed metabolomic analysis on 100 participants from an independent validation cohort (Supplementary Datas 11, 12).”
InfluentialCenci, C., Antonucci, E., Grifoni, E., Arcangeli, C., Prisco, D., Abbate, R., Miniati, M., & Poli, D. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-07-0534 · Cited by 38
“Perfusion lung scintigraphy was obtained in 235 of 236 patients after a median time of 11 months (3-80) from the index event.”
BackgroundMethodTreatment of established thrombotic events in patients with cancer
Lee, A. Y. Y. (2012) · Thrombosis Research · doi:10.1016/s0049-3848(12)70035-x · Cited by 39
“In contrast to patients with unprovoked thrombosis in whom an elevated D-dimer level indicates prolonging the duration of anticoagulation is beneficial in preventing recurrence [22], cancer patients often have elevated concentrations of D-dimer and other markers of coagulation activation even in the absence of thrombo…”
BackgroundEgan, P., & Reagan, J. L. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s150807 · Cited by 37
Recommendations from the ICM-VTE: General
Delegates, T. I.-V. G. (2022) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.21.01531 · Cited by 38
Tumor-Specific D-Dimer Concentration Ranges and Influencing Factors: A Cross-Sectional Study
Yu, J., Li, D., Lei, D., Yuan, F., Pei, F., Zhang, H., Yu, A., Wang, K., Chen, H., Chen, L., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165390 · Cited by 36
Tetzlaff, E. D., Correa, A. M., Baker, J. S., Ensor, J., & Ajani, J. A. (2007) · Cancer · doi:10.1002/cncr.22626 · Cited by 35
“treated previously for at least 3 months with a vitamin K antagonist.(13) Patients with abnormal D-dimer”
MethodArachchillage, D. J., Efthymiou, M., Mackie, I. J., Lawrie, A. S., Machin, S. J., & Cohen, H. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.11.037 · Cited by 35
“2 and D-dimer in identifying patients at increased risk of VTE recurrence who need continued anticoagulation, or a different intensity anticoagulant regime [7–9].”
BackgroundLegnani, C., Cini, M., Cosmi, B., Carraro, P., Tripodi, A., Erba, N., & Palareti, G. (2011) · Internal and Emergency Medicine · doi:10.1007/s11739-011-0608-5 · Cited by 36
Self-citationLong-term clinical course of acute pulmonary embolism
den Exter, P. L., van der Hulle, T., Lankeit, M., Huisman, M. V., & Klok, F. A. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.06.003 · Cited by 42
“Of these, D-dimer has been most extensively studied and appears to be the most promising predictor [12,18–20].”
BackgroundRole of selectins and fibrinolysis in VTE
Wakefield, T. W., Myers, D. D., & Henke, P. K. (2009) · Thrombosis Research · doi:10.1016/s0049-3848(09)70141-0 · Cited by 34
Mai, V., Bertoletti, L., Cucherat, M., Mainbourg, S., Grangé, C., Provencher, S., & Lega, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214134 · Cited by 35
Extended Anticoagulation for VTE
Mai, V., Guay, C.-A., Perreault, L., Bonnet, S., Bertoletti, L., Lacasse, Y., Mainbourg, S., Lega, J., & Provencher, S. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.02.402 · Cited by 38
Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation
Barnes, G. D., Kanthi, Y. M., & Froehlich, J. B. (2015) · Vascular Medicine · doi:10.1177/1358863x14566429 · Cited by 40
Cosmi, B., Legnani, C., Tosetto, A., Pengo, V., Ghirarduzzi, A., Alatri, A., Prisco, D., Poli, D., Tripodi, A., & Palareti, G. (2009) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-009-0315-5 · Cited by 33
Self-citationUnraveling the thrombophilia paradox: from hypercoagulability to the prothrombotic state
Baglin, T. P. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03702.x · Cited by 32
Postoperative pulmonary embolism: timing, diagnosis, treatment, and outcomes
Hope, W. W., Demeter, B. L., Newcomb, W. L., Schmelzer, T. M., Schiffern, L. M., Heniford, B. T., & Sing, R. F. (2007) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2007.08.014 · Cited by 32
Prandoni, P., Vedovetto, V., Ciammaichella, M. M., Bucherini, E., Corradini, S., Enea, I., Cosmi, B., Mumoli, N., Visonà, A., Barillari, G., et al. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.04.002 · Cited by 36
Self-citationOptimal Duration of Anticoagulation After Venous Thromboembolism
Goldhaber, S. Z., & Piazza, G. (2011) · Circulation · doi:10.1161/circulationaha.110.970822 · Cited by 33
Incidence and Risk Factors of the Post-thrombotic Syndrome
Wolf, M. A., Wittens, C. H. A., & Kahn, S. R. (2012) · Phlebology The Journal of Venous Disease · doi:10.1258/phleb.2011.012s06 · Cited by 35
Duration of Anticoagulation Therapy for Venous Thromboembolism
Bounameaux, H., & Perrier, A. (2008) · Hematology · doi:10.1182/asheducation-2008.1.252 · Cited by 32
High D-dimer levels after stopping anticoagulants in pulmonary embolism with sleep apnoea
Suquia, A. G., Alonso‐Fernández, A., de la Peña, M., Romero, D., Piérola, J., Carrera, M., Barceló, A., Soriano, J. B., Arqué, M., Fernández‐Capitán, C., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.02041-2014 · Cited by 34
Ryland, J., Lawrie, A. S., Mackie, I. J., & Machin, S. J. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2011.07.020 · Cited by 32
Thrombin generation assays to personalize treatment in bleeding and thrombotic diseases
Valke, L. L. F. G., Rijpma, S. R., Meijer, D., Schols, S. E. M., & van Heerde, W. L. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1033416 · Cited by 29
“Patients with an elevated D-dimer level who restarted anticoagulation had a significant lower chance of recurrent VTE than patients without anticoagulation (115).”
BackgroundNagler, M., Bachmann, L. M., Schmid, P., Müller, P. R., & Wuillemin, W. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095761 · Cited by 29
“We selected six major studies, investigating the efficacy of Rivaroxaban 20 mg, Apixaban 10 mg, Warfarin or another VKA and Dabigatran 150 mg to reduce the occurrence of recurrent thromboembolism and enrolling 9,872 patients were used for the analysis [31–36].”
MethodPredicting the risk of recurrent venous thromboembolism (VTE)
Streiff, M. B. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1188-4 · Cited by 32
Fan, J., Li, X., Cheng, Y., Yao, C., & Zhong, N. (2011) · Clinical and investigative medicine · doi:10.25011/cim.v34i1.15106 · Cited by 29
“D-dimer levels have increasingly been studied as markers of coagulation activation in several clinical scenarios [9-11].”
BackgroundUsing the laboratory to predict recurrent venous thrombosis
Baglin, T. P. (2011) · International Journal of Laboratory Hematology · doi:10.1111/j.1751-553x.2011.01345.x · Cited by 32
“In a series of studies from observation through to a patient management study (PROLONG), Palareti et al. showed that measurement of D-dimer levels following cessation of anticoagulant therapy predicts likelihood of recurrent thrombosis (Palareti et al., 2002, 2003, 2006).”
BackgroundVlieg, A. V. H., Baglin, C., Bare, L. A., Rosendaal, F. R., & Baglin, T. P. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.02920.x · Cited by 29
Kaczyńska, A., Kostrubiec, M., Pacho, R., Kunikowska, J., & Pruszczyk, P. (2007) · Thrombosis Research · doi:10.1016/j.thromres.2007.08.020 · Cited by 29
Thrombin generation: a global coagulation procedure to investigate hypo- and hyper-coagulability
Tripodi, A. (2020) · Haematologica · doi:10.3324/haematol.2020.253047 · Cited by 29
“measurements simultaneously can improve risk prediction in individual patients.(18)”
BackgroundSelf-citationD-dimer for prediction of long-term outcome in cryptogenic stroke patients with patent foramen ovale
Kim, Y. D., Song, D., Nam, H. S., Lee, K., Yoo, J., Hong, G., Lee, H. S., Nam, C. M., & Heo, J. H. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-12-1040 · Cited by 28
“4 years (35) and an extended follow-up over an average of 2.”
BackgroundExtended anticoagulation after venous thromboembolism: should it be done?
Fernandes, C. J. C. D. S., Calderaro, D., Piloto, B. M., Hoette, S., Jardim, C., & Souza, R. (2019) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466619878556 · Cited by 28
Poli, D., & Miniati, M. (2011) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328349289a · Cited by 28
East, A. T., & Wakefield, T. W. (2010) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2010.05.006 · Cited by 28
D‐dimer at venous thrombosis diagnosis is associated with risk of recurrence
Bjøri, E., Johnsen, H. S., Hansen, J., & Brækkan, S. K. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13648 · Cited by 35
Wakefield, T. W., Caprini, J. A., & Comerota, A. J. (2008) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2008.08.002 · Cited by 32
Novel Biomarkers Associated with Deep Venous Thrombosis: A Comprehensive Review
Barnes, D. M., Wakefield, T. W., & Rectenwald, J. E. (2008) · Biomarker Insights · doi:10.1177/117727190800300004 · Cited by 28
“[45] 608 patients with a fi rst episode of symptomatic, unprovoked venous thromboembolism were examined after completing at least 3 months of therapy with warfarin and were followed for a mean duration of 1.”
MethodIndefinite anticoagulation after a first episode of unprovoked venous thromboembolism: yes
Kearon, C. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02761.x · Cited by 30
Assessing recurrence risk following acute venous thromboembolism: use of algorithms
Poli, D., & Palareti, G. (2013) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328363ed7c · Cited by 28
Self-citationde Jong, P. G., Coppens, M., & Middeldorp, S. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09196.x · Cited by 29
“Indefinite duration of VKA at various intensities has been compared to durations of 3 or 6 months (Schulman et al, 1997; Kearon et al, 1999; Ridker et al, 2003; Farraj, 2004; Palareti et al, 2006).”
BackgroundMethodDiagnosis and Treatment of Lower Extremity Deep Vein Thrombosis: Korean Practice Guidelines
Kim, Y. H., Min, S., Kang, J. M., Kim, H.-K., Bae, J. I., Choi, S. Y., Park, S. J., Chang, J.-H., Park, U. J., Kim, C. W., et al. (2016) · Journal of the Korean Society of Radiology · doi:10.3348/jksr.2016.75.4.233 · Cited by 27
Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis
Wang, J. J., Knabb, R. M., Mohan, P., & Barrett, Y. C. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-06-0393 · Cited by 28
Dai, J., Qi, X., Peng, Y., Hou, Y., Chen, J., Li, H., & Guo, X. (2015) · PubMed · Cited by 27
Metadata
- Authors
- Palareti, G., Cosmi, B., Legnani, C., Tosetto, A., Brusi, C., Iorio, A., Pengo, V., Ghirarduzzi, A., Pattacini, C., Testa, S., Lensing, A. W. A., & Tripodi, A.
- Affiliations
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Ospedale San Bortolo (IT)
- University of Perugia (IT)
- Azienda Ospedale - Università Padova (IT)
- Santa Maria Nuova Hospital (IT)
- Istituti Ospitalieri di Cremona (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-10-26
- Volume
- 355
- Issue
- 17
- Pages
- 1780-1789
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2047986798
- Cited by
- 622
- References
- 25
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 12 · 2023: 11 · 2022: 14 · 2021: 16 · 2020: 34 · 2019: 22 · 2018: 20 · 2017: 19 · 2016: 40 · 2015: 41 · 2014: 40 · 2013: 38 · 2012: 53
- FWCI
- 35.51
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Cerebral Venous Sinus Thrombosis
- Keywords
- D-dimer, anticoagulation duration, venous thromboembolism, deep vein thrombosis, pulmonary embolism, vitamin K antagonists, recurrence, major bleeding, unprovoked thrombosis, anticoagulation resumption
- MeSH terms
- Acenocoumarol, Adult, Aged, Aged, 80 and over, Anticoagulants, Antithrombins, Drug Administration Schedule, Fibrin Fibrinogen Degradation Products, Follow-Up Studies, Hemorrhage, Humans, Middle Aged, Prospective Studies, Pulmonary Embolism, Recurrence, Ultrasonography, Vitamin K, Warfarin, Proportional Hazards Models, Survival Analysis, Antiphospholipid Syndrome, Venous Thrombosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.